Search in Medwell
 
 
Research Journal of Pharmacology
Year: 2018 | Volume: 12 | Issue: 2-6 | Page No.: 16-27
DOI: 10.36478/rjpharm.2018.16.27  
Do Histone Acetyltransferase Inhibitors Confer Neuroprotection Against Neurodegenerative Disorders? An Overview
Anna Capasso and Walter Milano
 
Abstract: Histone acetyltransferase inhibitors are able to induce neuroprotection because of their antioxidant properties, so, their therapeutic use in limiting neurological damage is strongly supported. Histone acetyltransferase inhibitors treatments should not only aim to alleviate specific symptoms but also, attempt to delay/arrest disease progression and to repair the damaged structures. The acetylation and deacetylation of histones are involved in the regulation of gene expression and the regular function of Histone Acetyltransferases (HATs) and Deacetylases (HDACs) provide regulatory steps for gene expression and cell cycle. Functional defects of these enzymes may lead to several diseases, including neurodegenerative disorders. The studies reported in the present review support the view that thehistone acetyltransferase inhibitors may be a key modulatory element in the control of neurodegenerative disorders. This idea is supported by different anatomical, electrophysiological, pharmacological and biochemical data. Furthermore, these studies support the idea of developing novel pharmacotherapies with histone acetyltransferase inhibitors that selectively target specific area of CNS.
 
How to cite this article:
Anna Capasso and Walter Milano, 2018. Do Histone Acetyltransferase Inhibitors Confer Neuroprotection Against Neurodegenerative Disorders? An Overview. Research Journal of Pharmacology, 12: 16-27.
DOI: 10.36478/rjpharm.2018.16.27
URL: http://medwelljournals.com/abstract/?doi=rjpharm.2018.16.27